During a median follow-up period of 3.7 years , the primary end point occurred in 769 of 7924 patients ( 9.7 % ) in the darapladib group and 819 of 7904 patients ( 10.4 % ) in the placebo group ( hazard ratio in the darapladib group , 0.94 ; 95 % confidence interval [ CI ] , 0.85 to 1.03 ; P = 0.20 ) .